The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection

Dawn M. Wetzel, Emma L. Rhodes, Shaoguang Li, Diane McMahon-Pratt, Anthony J. Koleske

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Leishmaniasis is a devastating disease that disfigures or kills nearly two million people each year. Establishment and persistence of infection by the obligate intracellular parasite Leishmania requires repeated uptake by macrophages and other phagocytes. Therefore, preventing uptake could be a novel therapeutic strategy for leishmaniasis. Amastigotes, the life cycle stage found in the human host, bind Fc receptors and enter macrophages primarily through immunoglobulin-mediated phagocytosis. However, the host machinery that mediates amastigote uptake is poorly understood.We have previously shown that the Arg (also known as Abl2) nonreceptor tyrosine kinase facilitates L. amazonensis amastigote uptake by macrophages. Using small-molecule inhibitors and primary macrophages lacking specific Src family kinases, we now demonstrate that the Hck, Fgr and Lyn kinases are also necessary for amastigote uptake by macrophages. Src-mediated Arg activation is required for efficient uptake. Interestingly, the dual Arg and Src kinase inhibitor bosutinib, which is approved to treat cancer, not only decreases amastigote uptake, but also significantly reduces disease severity and parasite burden in Leishmania-infected mice. Our results suggest that leishmaniasis could potentially be treated with host-cellactive agents such as kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)3130-3143
Number of pages14
JournalJournal of Cell Science
Volume129
Issue number16
DOIs
StatePublished - 2016

Fingerprint

src-Family Kinases
Leishmania
Phagocytosis
Immunoglobulin G
Macrophages
Leishmaniasis
Infection
Parasites
Phosphotransferases
Fc Receptors
Phagocytes
Life Cycle Stages
Protein-Tyrosine Kinases
Immunoglobulins
Neoplasms

Keywords

  • Abl
  • Kinase
  • Leishmania
  • Macrophage
  • Phagocytosis
  • Src

ASJC Scopus subject areas

  • Cell Biology

Cite this

The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection. / Wetzel, Dawn M.; Rhodes, Emma L.; Li, Shaoguang; McMahon-Pratt, Diane; Koleske, Anthony J.

In: Journal of Cell Science, Vol. 129, No. 16, 2016, p. 3130-3143.

Research output: Contribution to journalArticle

Wetzel, Dawn M. ; Rhodes, Emma L. ; Li, Shaoguang ; McMahon-Pratt, Diane ; Koleske, Anthony J. / The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection. In: Journal of Cell Science. 2016 ; Vol. 129, No. 16. pp. 3130-3143.
@article{6a64464160d34c14a44f201ff0dd41b4,
title = "The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection",
abstract = "Leishmaniasis is a devastating disease that disfigures or kills nearly two million people each year. Establishment and persistence of infection by the obligate intracellular parasite Leishmania requires repeated uptake by macrophages and other phagocytes. Therefore, preventing uptake could be a novel therapeutic strategy for leishmaniasis. Amastigotes, the life cycle stage found in the human host, bind Fc receptors and enter macrophages primarily through immunoglobulin-mediated phagocytosis. However, the host machinery that mediates amastigote uptake is poorly understood.We have previously shown that the Arg (also known as Abl2) nonreceptor tyrosine kinase facilitates L. amazonensis amastigote uptake by macrophages. Using small-molecule inhibitors and primary macrophages lacking specific Src family kinases, we now demonstrate that the Hck, Fgr and Lyn kinases are also necessary for amastigote uptake by macrophages. Src-mediated Arg activation is required for efficient uptake. Interestingly, the dual Arg and Src kinase inhibitor bosutinib, which is approved to treat cancer, not only decreases amastigote uptake, but also significantly reduces disease severity and parasite burden in Leishmania-infected mice. Our results suggest that leishmaniasis could potentially be treated with host-cellactive agents such as kinase inhibitors.",
keywords = "Abl, Kinase, Leishmania, Macrophage, Phagocytosis, Src",
author = "Wetzel, {Dawn M.} and Rhodes, {Emma L.} and Shaoguang Li and Diane McMahon-Pratt and Koleske, {Anthony J.}",
year = "2016",
doi = "10.1242/jcs.185595",
language = "English (US)",
volume = "129",
pages = "3130--3143",
journal = "Journal of Cell Science",
issn = "0021-9533",
publisher = "Company of Biologists Ltd",
number = "16",

}

TY - JOUR

T1 - The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection

AU - Wetzel, Dawn M.

AU - Rhodes, Emma L.

AU - Li, Shaoguang

AU - McMahon-Pratt, Diane

AU - Koleske, Anthony J.

PY - 2016

Y1 - 2016

N2 - Leishmaniasis is a devastating disease that disfigures or kills nearly two million people each year. Establishment and persistence of infection by the obligate intracellular parasite Leishmania requires repeated uptake by macrophages and other phagocytes. Therefore, preventing uptake could be a novel therapeutic strategy for leishmaniasis. Amastigotes, the life cycle stage found in the human host, bind Fc receptors and enter macrophages primarily through immunoglobulin-mediated phagocytosis. However, the host machinery that mediates amastigote uptake is poorly understood.We have previously shown that the Arg (also known as Abl2) nonreceptor tyrosine kinase facilitates L. amazonensis amastigote uptake by macrophages. Using small-molecule inhibitors and primary macrophages lacking specific Src family kinases, we now demonstrate that the Hck, Fgr and Lyn kinases are also necessary for amastigote uptake by macrophages. Src-mediated Arg activation is required for efficient uptake. Interestingly, the dual Arg and Src kinase inhibitor bosutinib, which is approved to treat cancer, not only decreases amastigote uptake, but also significantly reduces disease severity and parasite burden in Leishmania-infected mice. Our results suggest that leishmaniasis could potentially be treated with host-cellactive agents such as kinase inhibitors.

AB - Leishmaniasis is a devastating disease that disfigures or kills nearly two million people each year. Establishment and persistence of infection by the obligate intracellular parasite Leishmania requires repeated uptake by macrophages and other phagocytes. Therefore, preventing uptake could be a novel therapeutic strategy for leishmaniasis. Amastigotes, the life cycle stage found in the human host, bind Fc receptors and enter macrophages primarily through immunoglobulin-mediated phagocytosis. However, the host machinery that mediates amastigote uptake is poorly understood.We have previously shown that the Arg (also known as Abl2) nonreceptor tyrosine kinase facilitates L. amazonensis amastigote uptake by macrophages. Using small-molecule inhibitors and primary macrophages lacking specific Src family kinases, we now demonstrate that the Hck, Fgr and Lyn kinases are also necessary for amastigote uptake by macrophages. Src-mediated Arg activation is required for efficient uptake. Interestingly, the dual Arg and Src kinase inhibitor bosutinib, which is approved to treat cancer, not only decreases amastigote uptake, but also significantly reduces disease severity and parasite burden in Leishmania-infected mice. Our results suggest that leishmaniasis could potentially be treated with host-cellactive agents such as kinase inhibitors.

KW - Abl

KW - Kinase

KW - Leishmania

KW - Macrophage

KW - Phagocytosis

KW - Src

UR - http://www.scopus.com/inward/record.url?scp=84983671017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983671017&partnerID=8YFLogxK

U2 - 10.1242/jcs.185595

DO - 10.1242/jcs.185595

M3 - Article

VL - 129

SP - 3130

EP - 3143

JO - Journal of Cell Science

JF - Journal of Cell Science

SN - 0021-9533

IS - 16

ER -